FTα Activators
Chemical class FNTA Activators comprises compounds that indirectly influence FNTA activity, primarily through their impact on the biosynthesis of farnesyl pyrophosphate, the substrate for FNTA. These compounds, mostly statins and intermediates in the cholesterol biosynthesis pathway, do not directly activate FNTA but can increase the availability of its substrate, thereby potentially enhancing its enzymatic action.
The mechanism of action of these compounds is rooted in their influence on the mevalonate pathway, a key pathway in cholesterol biosynthesis. Statins, for example, are known to inhibit HMG-CoA reductase, the rate-limiting enzyme in this pathway. This inhibition can lead to a compensatory increase in the synthesis of intermediates upstream of the blockage, including farnesyl pyrophosphate. Thus, while statins primarily reduce cholesterol synthesis, their impact on the mevalonate pathway can indirectly lead to increased availability of farnesyl pyrophosphate, which might enhance FNTA activity.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Geranylgeranylpyrophosphate triammonium salt | 6699-20-3 | sc-200849 | 200 µg | $122.00 | ||
As a substrate for geranylgeranyltransferase, an increase in geranylgeranyl pyrophosphate levels can shift the balance of protein prenylation towards farnesylation, indirectly enhancing FNTA activity. | ||||||
D,L-Mevalonic Acid Dicyclohexylammonium Salt | 1215802-31-5 | sc-218048 sc-218048A sc-218048B sc-218048C sc-218048D | 100 mg 250 mg 500 mg 1 g 2.5 g | $338.00 $733.00 $1503.00 $2566.00 $5207.00 | ||
Mevalonic acid is a precursor in the cholesterol biosynthesis pathway, leading to the production of farnesyl pyrophosphate, a direct substrate for FNTA. | ||||||
Squalene | 111-02-4 | sc-281155 sc-281155A sc-281155B | 10 ml 100 ml 500 ml | $49.00 $92.00 $215.00 | 1 | |
As a precursor in the cholesterol biosynthesis pathway, squalene can increase the levels of farnesyl pyrophosphate, indirectly enhancing FNTA activity. | ||||||
Lovastatin | 75330-75-5 | sc-200850 sc-200850A sc-200850B | 5 mg 25 mg 100 mg | $29.00 $90.00 $339.00 | 12 | |
While primarily known as an inhibitor of HMG-CoA reductase, lovastatin can indirectly affect FNTA activity by modulating the levels of farnesyl pyrophosphate. | ||||||
Simvastatin | 79902-63-9 | sc-200829 sc-200829A sc-200829B sc-200829C | 50 mg 250 mg 1 g 5 g | $31.00 $89.00 $135.00 $443.00 | 13 | |
Simvastatin, similar to lovastatin, can influence FNTA activity indirectly through its effects on the cholesterol biosynthesis pathway. | ||||||
Atorvastatin | 134523-00-5 | sc-337542A sc-337542 | 50 mg 100 mg | $257.00 $505.00 | 9 | |
Atorvastatin affects cholesterol biosynthesis and can indirectly influence the levels of farnesyl pyrophosphate, affecting FNTA activity. | ||||||
Pravastatin, Sodium Salt | 81131-70-6 | sc-203218 sc-203218A sc-203218B | 25 mg 100 mg 1 g | $69.00 $162.00 $787.00 | 2 | |
Pravastatin, by modulating cholesterol biosynthesis, can indirectly affect the availability of FNTA's substrates. | ||||||
Rosuvastatin | 287714-41-4 | sc-481834 | 10 mg | $145.00 | 8 | |
This statin, through its impact on cholesterol biosynthesis, can indirectly influence FNTA activity. | ||||||
Fluvastatin | 93957-54-1 | sc-279169 | 50 mg | $250.00 | ||
Fluvastatin affects cholesterol biosynthesis, potentially altering the levels of substrates available for FNTA. | ||||||